Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective
Continued advances in microarray patch (MAP) technology are starting to make needle-free delivery of a broad range of vaccines an achievable goal. The drivers and potential benefits of a MAP platform for pandemic response and routine vaccination are clear and include dose-sparing, cold-chain elimina...
Main Authors: | Angus Forster, Michael Junger |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-11-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2022.2050123 |
Similar Items
-
Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study
by: B. Baker, et al.
Published: (2023-01-01) -
Microarray patches: scratching the surface of vaccine delivery
by: Jovin J. Y. Choo, et al.
Published: (2023-12-01) -
Usability, acceptability, and feasibility of a High-Density Microarray Patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings
by: Cristyn Davies, et al.
Published: (2022-11-01) -
Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial
by: Ben Baker, et al.
Published: (2023-11-01) -
Progress towards the Development of a Universal Influenza Vaccine
by: Wen-Chien Wang, et al.
Published: (2022-07-01)